Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

RESPONSIVE HEALTH LLC

NPI: 1780273839 · CAMDEN, DE 19934 · Clinical Medical Laboratory · NPI assigned 01/13/2021

Billing Flags · Automated signals — not evidence of fraud
Entity Proliferation

Authorized official NGUYEN, HIEN controls 12+ related entities in our dataset. Read more

$6.02M
Total Medicaid Paid
113,646
Total Claims
60,286
Beneficiaries
9
Codes Billed
2021-05
First Month
2024-12
Last Month

Provider Details

Authorized OfficialNGUYEN, HIEN (MANAGER)
NPI Enumeration Date01/13/2021

Related Entities

Other providers sharing the same authorized official: NGUYEN, HIEN

ProviderCityStateTotal Paid
EMPIRE MEDICAL LLC CAMDEN DE $6.93M
HIEN AND DIANE NGUYEN DENTAL CORPORATION EL MONTE CA $956K
H & M DENTAL LLC HENDERSON NV $724K
DELAWARE WALK-IN MEDICAL, LLC CAMDEN DE $396K
RESPONSIVE MEDICAL LLC CAMDEN DE $286K
SMILE DESIGN DENTAL, P.A. PLANO TX $252K
EYE MAX INC GLOUCESTER VA $180K
NEW HEALTH OF NORTH EAST, LLC ELKTON MD $40K
LUU & NGUYEN DENTAL CORPORATION CHULA VISTA CA $24K
ABSOLUTE FAMILY DENTAL CARE, PA SAN ANTONIO TX $3K
EYEMAX, INC. GLOUCESTER VA $3K
HELOTES COSMETIC & FAMILY DENTISTRY, PLLC HELOTES TX $176.40

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2021 26,340 $1.34M
2022 38,518 $2.02M
2023 28,367 $1.36M
2024 20,421 $1.30M

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 22,381 11,489 $2.03M
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 17,484 9,646 $1.17M
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 37,403 19,475 $971K
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 15,502 8,749 $948K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 20,151 10,310 $827K
99204 Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 521 458 $64K
99211 Office or other outpatient visit for the evaluation and management of an established patient, minimal severity 164 122 $3K
99203 Office or other outpatient visit for the evaluation and management of a new patient, low complexity 27 25 $1K
99215 Prolong outpt/office vis 13 12 $1K